Peripheral neuropathy medical therapy

Jump to navigation Jump to search

Peripheral neuropathy Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating peripheral neuropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Peripheral neuropathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Peripheral neuropathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peripheral neuropathy medical therapy

CDC on Peripheral neuropathy medical therapy

Peripheral neuropathy medical therapy in the news

Blogs on Peripheral neuropathy medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Peripheral neuropathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Pharmacologic medical therapy is recommended among patients with peripheral neuropathy. Peripheral neuropathy, caused by various central and peripheral nerve disorders, is especially problematic because of its severity, chronicity and resistance to simple analgesics. According to the cause of the peripheral neuropathy, treatments vary from the choice drug, the dosage of drug and the time of the treatment. Treatments for peripheral neuropathy are generally palliative. Pharmacologic medical therapies for peripheral neuropathy include: Topical lidocaine, Gabapentin, pregabalin, Amitriptyline, Nortriptyline, imipramine, mixed serotonin–norepinephrine reuptake inhibitors, Tramadol, buprenorphine, Oxycodone, Morphine, Hydrocodone and Codeine.

Medical Therapy

References

  1. 1.0 1.1 1.2 Gilron I, Watson CP, Cahill CM, Moulin DE (2006). "Neuropathic pain: a practical guide for the clinician". CMAJ. 175 (3): 265–75. doi:10.1503/cmaj.060146. PMC 1513412. PMID 16880448.
  2. Delorme C, Navez ML, Legout V, Deleens R, Moyse D (2011). "Treatment of neuropathic pain with 5% lidocaine-medicated plaster: Five years of clinical experience". Pain Res Manag. 16 (4): 259–63. PMC 3202378. PMID 22059196.
  3. Fornasari D (2017). "Pharmacotherapy for Neuropathic Pain: A Review". Pain Ther. 6 (Suppl 1): 25–33. doi:10.1007/s40122-017-0091-4. PMC 5701897. PMID 29178034.
  4. 4.0 4.1 Nishikawa T, Hasegawa K, Shintani D, Yano Y, Sato S, Yabuno A; et al. (2017). "[Combination Therapy of Pregabalin with Tramadol for Treatment of Peripheral Neuropathy in Patients with Gynecological Cancer Receiving Taxane Containing Chemotherapy]". Gan To Kagaku Ryoho. 44 (3): 227–231. PMID 28292992.
  5. Berger A, Dukes E, Edelsberg J, Stacey B, Oster G (2007). "Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy". Clin J Pain. 23 (3): 251–8. doi:10.1097/AJP.0b013e31802f67dd. PMID 17314585.
  6. Aziz MT, Good BL, Lowe DK (2014). "Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy". Ann Pharmacother. 48 (5): 626–32. doi:10.1177/1060028014525033. PMID 24577146.
  7. Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU (2009). "Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise". Curr Neuropharmacol. 7 (4): 331–6. doi:10.2174/157015909790031201. PMC 2811866. PMID 20514212.
  8. Raffa RB, Pergolizzi JV, Segarnick DJ, Tallarida RJ (2010). "Oxycodone combinations for pain relief". Drugs Today (Barc). 46 (6): 379–98. doi:10.1358/dot.2010.46.6.1470106. PMC 4046166. PMID 20571607.

Template:WH Template:WS